Oncogenic Transformation of Mesenchymal Stem Cells Decreases Nrf2 Expression Favoring in Vivo Tumor Growth and Poorer Survival

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2014 Feb 5

PMID 24491031

Citations 20

Authors

Juan M Funes

Stephen Henderson

Rachel Kaufman

James M Flanagan

Mathew Robson

Barbara Pedley

Salvador Moncada

Chris Boshoff

Affiliations

Soon will be listed here.

Abstract

Background: The transcription factor Nrf2 is a key regulator of the cellular antioxidant response, and its activation by chemoprotective agents has been proposed as a potential strategy to prevent cancer. However, activating mutations in the Nrf2 pathway have been found to promote tumorigenesis in certain models. Therefore, the role of Nrf2 in cancer remains contentious.

Methods: We employed a well-characterized model of stepwise human mesenchymal stem cell (MSC) transformation and breast cancer cell lines to investigate oxidative stress and the role of Nrf2 during tumorigenesis. The Nrf2 pathway was studied by microarray analyses, qRT-PCR, and western-blotting. To assess the contribution of Nrf2 to transformation, we established tumor xenografts with transformed MSC expressing Nrf2 (n = 6 mice per group). Expression and survival data for Nrf2 in different cancers were obtained from GEO and TCGA databases. All statistical tests were two-sided.

Results: We found an accumulation of reactive oxygen species during MSC transformation that correlated with the transcriptional down-regulation of antioxidants and Nrf2-downstream genes. Nrf2 was repressed in transformed MSC and in breast cancer cells via oncogene-induced activation of the RAS/RAF/ERK pathway. Furthermore, restoration of Nrf2 function in transformed cells decreased reactive oxygen species and impaired in vivo tumor growth (P = 0.001) by mechanisms that included sensitization to apoptosis, and a decreased hypoxic/angiogenic response through HIF-1α destabilization and VEGFA repression. Microarray analyses showed down-regulation of Nrf2 in a panel of human tumors and, strikingly, low Nrf2 expression correlated with poorer survival in patients with melanoma (P = 0.0341), kidney (P = 0.0203) and prostate (P = 0.00279) cancers.

Conclusions: Our data indicate that oncogene-induced Nrf2 repression is an adaptive response for certain cancers to acquire a pro-oxidant state that favors cell survival and in vivo tumor growth.

Citing Articles

1,4-Diol Hq (TBHQ) vs 1,4-dithiol (TBDT); simulation of safe antioxidant with a lower carcinogenic activity.

Mosavi S, Hosseinzadeh Colagar A, Zahedi T, Seyedalipour B Sci Prog. 2024; 107(3):368504241280869.

PMID: 39314158 PMC: 11445769. DOI: 10.1177/00368504241280869.

Targeting Nrf2 and NF-κB Signaling Pathways in Cancer Prevention: The Role of Apple Phytochemicals.

Gado F, Ferrario G, Della Vedova L, Zoanni B, Altomare A, Carini M Molecules. 2023; 28(3).

PMID: 36771023 PMC: 9919881. DOI: 10.3390/molecules28031356.

The dual role of Nrf2 in melanoma: a systematic review.

Malakoutikhah Z, Mohajeri Z, Dana N, Javanmard S BMC Mol Cell Biol. 2023; 24(1):5.

PMID: 36747120 PMC: 9900951. DOI: 10.1186/s12860-023-00466-5.

A new frontier in temporomandibular joint osteoarthritis treatment: Exosome-based therapeutic strategy.

Yuan W, Wu Y, Huang M, Zhou X, Liu J, Yi Y Front Bioeng Biotechnol. 2022; 10:1074536.

PMID: 36507254 PMC: 9732036. DOI: 10.3389/fbioe.2022.1074536.

NRF2: A crucial regulator for mitochondrial metabolic shift and prostate cancer progression.

Buttari B, Arese M, Oberley-Deegan R, Saso L, Chatterjee A Front Physiol. 2022; 13:989793.

PMID: 36213236 PMC: 9540504. DOI: 10.3389/fphys.2022.989793.

References

Ramos-Gomez M, Kwak M, Dolan P, Itoh K, Yamamoto M, Talalay P . Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A. 2001; 98(6):3410-5. PMC: 30667. DOI: 10.1073/pnas.051618798. View

Funes J, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C . Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A. 2007; 104(15):6223-8. PMC: 1851087. DOI: 10.1073/pnas.0700690104. View

Chinery R, Brockman J, Peeler M, Shyr Y, Beauchamp R, Coffey R . Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med. 1997; 3(11):1233-41. DOI: 10.1038/nm1197-1233. View

Lau A, Villeneuve N, Sun Z, Wong P, Zhang D . Dual roles of Nrf2 in cancer. Pharmacol Res. 2008; 58(5-6):262-70. PMC: 2652397. DOI: 10.1016/j.phrs.2008.09.003. View

Venugopal R, Jaiswal A . Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci U S A. 1996; 93(25):14960-5. PMC: 26245. DOI: 10.1073/pnas.93.25.14960. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

McMahon M, Itoh K, Yamamoto M, Hayes J . Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003; 278(24):21592-600. DOI: 10.1074/jbc.M300931200. View

Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H . Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012; 22(1):66-79. DOI: 10.1016/j.ccr.2012.05.016. View

Nioi P, Nguyen T . A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun. 2007; 362(4):816-21. DOI: 10.1016/j.bbrc.2007.08.051. View

10.

Niture S, Jaiswal A . Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J Biol Chem. 2012; 287(13):9873-9886. PMC: 3323009. DOI: 10.1074/jbc.M111.312694. View

11.

Yaari-Stark S, Shaked M, Nevo-Caspi Y, Jacob-Hircsh J, Shamir R, Rechavi G . Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. Int J Cancer. 2009; 126(10):2268-81. DOI: 10.1002/ijc.25102. View

12.

Wang X, Tomso D, Chorley B, Cho H, Cheung V, Kleeberger S . Identification of polymorphic antioxidant response elements in the human genome. Hum Mol Genet. 2007; 16(10):1188-200. PMC: 2805149. DOI: 10.1093/hmg/ddm066. View

13.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

14.

Kwak M, Kensler T . Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2009; 244(1):66-76. PMC: 3584341. DOI: 10.1016/j.taap.2009.08.028. View

15.

Zhang D . Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev. 2006; 38(4):769-89. DOI: 10.1080/03602530600971974. View

16.

Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y . An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236(2):313-22. DOI: 10.1006/bbrc.1997.6943. View

17.

Satoh H, Moriguchi T, Taguchi K, Takai J, Maher J, Suzuki T . Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis. 2010; 31(10):1833-43. DOI: 10.1093/carcin/bgq105. View

18.

Kensler T, Wakabayashi N . Nrf2: friend or foe for chemoprevention?. Carcinogenesis. 2009; 31(1):90-9. PMC: 2802668. DOI: 10.1093/carcin/bgp231. View

19.

Zhang Y, Gordon G . A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol Cancer Ther. 2004; 3(7):885-93. View

20.

Singh A, Misra V, Thimmulappa R, Lee H, Ames S, Hoque M . Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3(10):e420. PMC: 1584412. DOI: 10.1371/journal.pmed.0030420. View